Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis

Rheumatology

Volumn 47, Issue 4, 2008, Pages 392-398

  Emery, P ^d   McInnes, I B ^a   van Vollenhoven, R ^b   Kraan, M C ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Global Medical Affairs   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Biologic therapy; Disease progression; Inflammation; Rheumatoid arthritis

Indexed keywords

ACUTE PHASE PROTEIN; ADALIMUMAB; AGGRECAN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; BONE SIALOPROTEIN; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; GADOLINIUM; HLA DR4 ANTIGEN; HYALURONIC ACID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PREDNISOLONE; PYRIDINOLINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; SERUM AMYLOID P; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INDIVIDUALIZATION; JOINT RADIOGRAPHY; MEDICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; DRUG ANTAGONISM; HOSPITALIZATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43049158205     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem257     Document Type: Review

References (66)

1. Emery P. The Dunlop-Dottridge Lecture: Prognosis in inflammatory arthritis: The value of HLA genotyping and oncological analogy. J Rheumatol 1997;24:1436-42.
2. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
3. Tortora G, Derrickson B. Principles of anatomy and physiology, 11th edn. Hoboken, NJ: John Wiley and Sons, 2006.
4. Takasugi K, Yamamura M, Iwahashi M et al. Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis. Arthritis Res Ther 2006;8:R126.
5. Boers M, Kostense PJ, Verhoeven AC, van der Linden S. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 2001;44:2242-6.
6. Jenkins JK, Hardy KJ, McMurray RW. The pathogenesis of rheumatoid arthritis: A guide to therapy. Am J Med Sci 2002;323:171-80.
7. Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol 2001;28:881-6.
8. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral for newly diagnosed rheumatoid arthritis: Evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
9. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
10. Vilette D, Setiadi H, Wautier MP, Caen J, Wautier JL. Identification of an endothelial cell growth-inhibitory activity produced by human monocytes. Exp Cell Res 1990;188:219-25.
11. Kraan MC, Versendaal H, Jonker M et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41:1481-8.
12. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
13. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
14. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
15. Lipsky PE, van der Heijde DMFM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
16. St Clair EW, van der Heijde DM, Smolen JS et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004;50:3432-43.
17. Verstappen SMM, Poole AR, Ionescu M et al. Utrecht Rheumatoid Arthritis Cohort Study group (SRU). Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be detected by serum biomarkers: An evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006;8:1-9.
18. Roux-Lombard P, Eberhardt K, Saxne T, Dayer JM, Wollheim FA. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: Relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology 2001;40:544-51.
19. Smolen JS, van der Heijde DM, St Clair EW et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE Trial. Arthritis Rheum 2006;54:702-10.
20. van Leeuwen MA, van Rijswijk MH, van der Heijde DM et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease. Br J Rheumatol 1993(32 Suppl 3):9-13.
21. Stenger AA, van Leeuwen MA, Houtman PM et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
22. van der Horst-Bruinsma IE, Speyer I, Visser H, Breedveld FC, Hazes JM. Diagnosis and course of early onset arthritis: Results from a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998;37:1084-8.
23. Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003;30:2350-5.
24. Garnero P, Geusens P, Landewé R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S54-8.
25. Nakamura RM. Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis. J Clin Lab Anal 2000;14:305-13.
26. Dieude P, Corneilis F. Genetic basis of rheumatoid arthritis. Joint Bone Spine 2005;72:520-6.
27. Hoet RM, Venrooij V. The antiperinuclear factor and antikeratin antibodies in rheumatoid arthritis. In: Smoker J, Kalden J, Maini RM, eds. Rheumatoid arthritis. Berlin: Springer-Verlag, 1992;299-318.
28. Sebbag M, Simon M, Vincent C et al. The antiperinuclear factor and so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995;95:2672-9.
29. Schellekens GA, de Jong BA, van de Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
30. Ronnelid J, Wick MC, Lampa J et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
31. Kamali S, Polat NG, Kasapoglu E et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjogren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005;24:673-6.
32. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiological progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-7.
33. van Leeuwen MA, van Rijswijk MH, Sluiter WJ et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
34. Åman S, Paimela L, Leirisalo-Repo M et al. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study. Rheumatology 2000;39:1009-13.
35. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA. Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 2000;59:223-6.
36. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-7.
37. Devlin J, Gough A, Huissoon A et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997;24:9-13.
38. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
39. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
40. Mansson B, Geboreck P, Saxne T. Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: Relation to development of knee or hip joint destruction. Ann Rheum Dis 1997;56:91-6.
41. Mansson B, Carey D, Alini M et al. Cartilage and bone metabolism in RA. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
42. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21-30.
43. Landewé R, van der Heijde D. Radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S63-8.
44. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
45. Conaghan PG, Quinn MA, O'Connor P, Wakefield RJ, Karim Z, Emery P. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? Arthritis Rheum 2002;46:1971-2.
46. Kim JM, Weisman MH. When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000;43:473-84.
47. Shergy WJ, Isern RA, Cooley DA et al. PROMPT Study Group. Profiling Remicade onset with MTX in a prospective trial. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002;29:667-77.
48. Grigor C, Capell H, Stirlin A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomized controlled trial. Lancet 2004;364:263-9.
49. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34(Suppl 1):7-11.
50. Aetna. Remicade: Clinical Policy Document. 28 October 2005. 0341 Revised.
51. Keystone E. Reality-based algorithm for treating with biologics. Paper presented at: TNF inhibitors: A new era in the treatment of rheumatoid arthritis, 2005; Vienna, Austria.
52. Smolen JS, Han C, Bala M et al. ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement. Arthritis Rheum 2005;52:1020-30.
53. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004;50:1400-11.
54. Klareskog L, van der Heijde D, de Jager JP et al. TEMPO (Trial of etanercept and methotrexate with radiographic patient outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363:675-81.
55. Maini RN, Breedveld FC, Kalden JR et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
56. Familian A, Voskuyl AE, van Mierlo GJ et al. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:1003-8.
57. Buch MH, Seto Y, Bingham SJ et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis. Arthritis Rheum 2005;52:42-8.
58. Breedveld FC, Emery P, Keystone E et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
59. St Clair EW, Wagner CL, Fasanmade AA et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
60. Hermann J, Mueller T, Fahrleitner A, Dimai HP. Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab. Clin Exp Rheumatol 2003;21:473-6.
61. Zamarron C, Maceiras F, Mera A, Gomez-Reino JJ. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:88-90.
62. Smeets TJM, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor α blockade reduces synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-62.
63. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
64. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
65. McInnes IB. Attitudes of rheumatologists to rapidly progressing rheumatoid arthritis. Rheumatology 2007;46(4 Suppl 1):aBstract #205.
66. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, Group FS. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: The BeSt study. Clin Exp Rheumatol 2006;24(6 Suppl 43):S77-82.